Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...
MPR

Litifilimab Receives FDA Breakthrough Status for Cutaneous Lupus

Litifilimab is a humanized IgG1 monoclonal antibody targeting the BDCA2 receptor to reduce proinflammatory mediators in cutaneous lupus erythematosus.
News Medical

Researchers uncover and inhibit a key cell death pathway in severe cutaneous adverse reactions

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate ...
ascopubs.org

Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid tumors, making it an attractive target for anticancer therapy. A number of agents that target this receptor are in ...
EurekAlert!

Development of new candidate agent for lethal and severe cutaneous drug reaction

Niigata, Japan - A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata ...
Medical Xpress

Experimental inhibitor reduces cell death in models of life-threatening skin reactions

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic ...
ascopubs.org

Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 ...

Lung and bronchus cancer in young females: Exploring sex disparities across diverse racial and ethnic groups in the U.S. (2000-2020). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...
Cure Today

FDA Approves Lymphir for Relapsed, Refractory Cutaneous T-Cell Lymphoma

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma. The Food and Drug Administration has approved Lymphir (denileukin ...